bictegravir
Biktarvy’s Benefits Extend in Older Adults With HIV
Five-year follow-up data from the triple combination HIV therapy bictegravir-emtricitabine-tenofavir alafenamide ...
NOVEMBER 26, 2024
Long-Acting Injectable ART as Effective as Daily Pills
CAB+RPV LA antiretroviral therapy was as effective as daily BIC/FTC/TAF in maintaining viral suppression among ...
FEBRUARY 23, 2023
Switching HIV Regimen Found Safe
Switching to the newly approved Biktarvy in virologically suppressed adults maintained viral suppression with fewer ...
MARCH 7, 2018
ViiV Files Suit Against Gilead Over HIV Drug Patents
ViiV claims bictegravir infringes on its patent covering dolutegravir and many other compounds that include ...
FEBRUARY 8, 2018
Bictegravir-Containing Compound Looks Promising for HIV
Bictegravir is a novel, potent integrase strand transfer inhibitor (INSTI), which features a high in vitro barrier ...
OCTOBER 10, 2017
Good Virologic Response Seen for Bictegravir in HIV
News from CROI 2017: Gilead's novel, investigational drug appears to be promising in rapidly suppressing HIV.
FEBRUARY 15, 2017
